{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:02:12Z","timestamp":1770480132951,"version":"3.49.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,30]],"date-time":"2006-06-30T00:00:00Z","timestamp":1151625600000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p><jats:bold><jats:sc>Abstract:\u2002<\/jats:sc><\/jats:bold>  <jats:bold>Cardiovascular morbidity and mortality appear to be increased in rheumatoid arthritis (RA), which might be due to increased prevalence of risk factors for cardiovascular disease, such as an accelerated progression of atherosclerosis. Patients with active RA frequently show an atherogenic lipid profile, which has been linked with the inflammatory reaction. Tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1), a pivotal proinflammatory cytokine implicated in the pathogenesis of atherosclerosis in RA, may be involved in the development of the altered lipid profile observed in active RA. Our aim was to investigate the effects of anti\u2010TNF\u2010\u03b1 treatment in combination with methotrexate (MTX) and corticosteroid therapy on lipid profile in patients with active RA. In this prospective study 34 consecutive RA patients were included (all women, mean age 51.6 \u00b1 7.9 years, range 46\u201372 years) with active (defined as Disease Activity Index 28 joint score [DAS\u201028], of at least 3.2) and refractory RA, in stable treatment with MTX (7.5\u201310 mg\/week) and prednisone (7.5\u201310 mg\/day) for 3 months. All patients received TNF\u2010\u03b1 blockers (<jats:italic>n<\/jats:italic>= 16, etanercept 25 mg twice weekly; <jats:italic>n<\/jats:italic>= 14, infliximab 3 mg\/kg on 0, 2, 6, and every 8 weeks thereafter; and finally, <jats:italic>n<\/jats:italic>= 4, adalimumab 40 mg every other week). Total cholesterol, high\u2010density lipoprotein cholesterol (HDL cholesterol), triglycerides (TG) and lipoprotein (a) [Lp(a)] levels and the atherogenic index (ratio cholesterol\/HDL cholesterol) were measured at base line, and at 16 and 24 weeks. Results were as follows: The DAS\u201028 was 6.9 \u00b1 2.1 at base line and decreased to 4.6 \u00b1 1.8 after 16 weeks, and further to 4.1 \u00b1 1.3 after 24 weeks (both, <jats:italic>P<\/jats:italic> &lt; 0.01). Following anti\u2010TNF\u2010\u03b1 treatment, the mean levels of total cholesterol were 168 \u00b1 24 mg\/dL at base line and increased to 188 \u00b1 28 mg\/dL at 16 weeks (<jats:italic>P<\/jats:italic> &lt; 0.01), and 197 \u00b1 26 mg\/dL at 24 weeks (<jats:italic>P<\/jats:italic> &lt; 0.001). However, also the mean levels of HDL cholesterol were significantly higher than basal values after 16 and 24 weeks of treatment (34 \u00b1 12 mg\/dL versus 36 \u00b1 18 mg\/dL [<jats:italic>P<\/jats:italic> &lt; 0.05] and 38 \u00b1 14 mg\/dL [<jats:italic>P<\/jats:italic> &lt; 0.01], respectively). TG and Lp(a) levels, as well as the atherogenic index were not significantly changed. Interestingly, variations in disease activity were significantly and inversely correlated with HDL cholesterol levels. In conclusion: Short anti\u2010TNF\u2010\u03b1 treatment was associated with a significant increase of both total cholesterol and HDL cholesterol levels, and correlated with decreased disease activity. The atherogenic index showed no changes during the study. Therefore, anti\u2010TNF\u2010\u03b1 treatment might affect lipid profile in RA patients.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1351.039","type":"journal-article","created":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T19:35:49Z","timestamp":1153337749000},"page":"414-419","source":"Crossref","is-referenced-by-count":98,"title":["Effects of Anti\u2010TNF\u2010\u03b1 Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis"],"prefix":"10.1111","volume":"1069","author":[{"given":"BRUNO","family":"SERIOLO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SABRINA","family":"PAOLINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ALBERTO","family":"SULLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DANIELA","family":"FASCIOLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAURIZIO","family":"CUTOLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,30]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1196","article-title":"All\u2010cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database","volume":"30","author":"Watson D.J.","year":"2003","journal-title":"J. Rheumatol"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20636"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10089"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200203000-00007"},{"key":"e_1_2_5_6_2","first-page":"406","article-title":"Lipid profile and anticardiolipin antibodies in rheumatoid arthritis","volume":"13","author":"Seriolo B.","year":"1995","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000053730.47739.3C"},{"key":"e_1_2_5_8_2","first-page":"252","article-title":"Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis","volume":"32","author":"Vis M.","year":"2005","journal-title":"J. Rheumatol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/clinchem\/43.4.663","article-title":"Precipitation methods for high\u2010density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample to reagent ratio","volume":"43","author":"Demacker P.N.M.","year":"1997","journal-title":"Clin. Chem"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1055\/s-0038-1649819","article-title":"Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis","volume":"74","author":"Seriolo B.","year":"1995","journal-title":"Thromb. Haemost"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10269"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11078"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037521.71373.44"},{"key":"e_1_2_5_14_2","first-page":"1004","article-title":"Intravenous anti\u2010TNF\u03b1 antibody therapy leads to elevated triglyceride and reduced HDL\u2010cholesterol levels in patients with rheumatoid arthritis and psoriatic arthritis","volume":"114","author":"Cauza E.","year":"2002","journal-title":"Wien. Klin. Wochenschr"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023119"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1351.039","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1351.039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T19:29:47Z","timestamp":1695670187000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1351.039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1196\/annals.1351.039"],"URL":"https:\/\/doi.org\/10.1196\/annals.1351.039","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}